Alterations in ATC/DDD
Overview of ATC/DDD alterations decided at the two previous meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC/DDD alterations from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the alterations will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.
Please note that all ATC alterations are valid and implemented annually.
Change in ATC codes
|INN/generic name||Previous ATC code||New ATC code||Deadline for objection to temporary alterations 1)||Implementation in ATC/DDD index|
|calcium acetate 2)||A12AA12||V03AE07||01.09.2015||2016|
Change of ATC level name
|Previous name||New ATC level name||ATC code||Deadline for objection to temporary alterations||Implementation in ATC/DDD index|
Change of DDDs
|ATC code||Level name||Previous DDD||New DDD||Deadline for objection to temporary alterations 1)||Implementation in ATC/DDD index|
|B01AE07||dabigatran etexilate||0.22 g O||0.3 g O||01.09.2015||2016|
|B01AF01||rivaroxaban||10 mg O||20 mg O||01.09.2015||2016|
|B01AF02||apixaban||5 mg O||10 mg O||01.09.2015||2016|
|G03GA02||Human menopausal gonadotrophin||30 U P||75 U P||01.09.2015||2016|
2) Previous ATC level name: calcium acetate anhydrous
Last updated: 2015-04-29